GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate

The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's GOVX modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite.
GeoVax's MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite's life cycle.
They are designed to induce an immune response with durable functional antibodies and CD4+ and CD8+ T cell responses.
GeoVax's GV-MVA-VLP vaccine platform utilizes modified vaccinia Ankara (MVA), a large virus capable of carrying several vaccine antigens, expressing proteins that assemble into virus-like particles (VLP) immunogens in the person receiving the vaccine.
The production of VLPs in the person being vaccinated can mimic the virus production that occurs in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.
Price Action: GOVX shares are up 22.80% at $1.06 during the market session on the last check Tuesday.